STAMFORD, Conn., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical ...
Q4 and 2H 2017 Afrezza net revenue were $4.5 million (+238%) and $6.4 million ...
HalioDx performed development work for ipsogen® JAK2 510(k) clearance by QIAGEN HalioDx has ...
